Literature DB >> 6451199

Abnormalities of immunoregulation in progressive systemic sclerosis. Evidence for excess helper-cell function and altered B-cell function.

R S Krakauer, J Sundeen, D N Sauder, A Scherbel.   

Abstract

We investigated immunoregulatory function in patients with progressive systemic sclerosis (PSS) in terms of in vitro IgM synthesis. Suppressor-cell function seems normal in regard to the ability of concanavalin A-treated cells to inhibit IgM synthesis by normal cells. At 4 x 10(5) T cells to 3 x 10(5) allogeneic normal B cells per milliliter, T cells from patients with PSS induce significantly more IgM synthesis by normal B cells than do normal T cells. This increased helper T-cell function might be involved in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6451199

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

1.  An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.

Authors:  N Giordano; G Biasi; A Taddeo; R Marcolongo; D Bertelletti
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

2.  Lymphocytotoxic autoantibodies in progressive systemic sclerosis.

Authors:  K Herrmann; J Schaller; U F Haustein; C Baldauf; S Kiessig
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

Review 3.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

4.  Correction of a suppressor cell deficiency in four patients with familial Mediterranean fever by in vitro or in vivo colchicine.

Authors:  D Ilfeld; O Kuperman
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

5.  Detection of antilymphocyte antibodies in patients with scleroderma using three different techniques.

Authors:  M T Labro; A Perianin; M F Kahn
Journal:  Clin Rheumatol       Date:  1984-12       Impact factor: 2.980

6.  Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases.

Authors:  A Laffón; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

7.  Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis.

Authors:  T Herlin; J Eggert; K Kragballe; H Zachariae
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

8.  Spontaneous production of, and defective response to, interleukin-1 by peripheral blood mononuclear cells from patients with scleroderma.

Authors:  J Alcocer-Varela; E Martinez-Cordero; D Alarcon-Segovia
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

9.  Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus.

Authors:  F Drenk; H Mensing; A Serbin; H Deicher
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

10.  Recognition of major histocompatibility complex antigens on murine glial cells.

Authors:  G Birnbaum; B Clinchy; M B Widmer
Journal:  J Neuroimmunol       Date:  1986-09       Impact factor: 3.478

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.